Table 3

The frequency of mRNA decrease (FD) and the average level of mRNA decrease (LDav)

Clinical stage/Groups

Frequency (FD)a and level of mRNA decrease (LDav)b

RBSP3

(59 tumors)

NPRL2

(59 tumors)

RASSF1A

(36 tumors)

AC

SCC

AC

SCC

AC

SCC


I

FD

LDav

*71 (5/7)

*3 (2 -- 6)

*100 (11/11)

*7 (2 -- 23)

14 (1/7)

2

*100 (11/11)

*7 (2 -- 100)

29 (2/7)

4 (3 -- 5)

33 (2/6)

4 (2 -- 8)

II

FD

LDav

*60 (3/5)

*5 (2 -- 9)

*79 (15/19)

*4 (2 -- 11)

40 (2/5)

6 (5--7)

*74 (14/19)

*9 (2 -- 100)

100 (1/1)

6

80 (4/5)

5 (2 -- 8)

III

FD

LDav

*100 (6/6)

*6 (2 -- 26)

*91 (10/11)

*8 (2 -- 94)

*83 (5/6)

*4 (2 -- 7)

*91 (10/11)

*10 (2 -- 100)

*100 (6/6)

*7 (3 -- 21)

*82 (9/11)

*7 (2 -- 57)

Group without metastasis

FD

LDav

    *70 (7/10)

    *3 (2 -- 6)

*88 (21/24)

*5 (2 -- 23)

    *20 (2/10)

*4 (2 -- 7)

*88 (21/24)

*10 (2 -- 100)

29 (2/7)

4 (3 -- 6)

    33 (2/6)

    4 (2 -- 8)

Group with metastasis

FD

LDav

    *88 (7/8)

    *6 (2 -- 26)

*88 (15/17)

*7 (2 -- 94)

    *75 (6/8)

*4 (2 -- 7)

*82 (14/17)

*8 (2 -- 100)

*100 (7/7)

*7 (3 -- 21)

    *81 (13/16)

    *6 (2 -- 57)

Total

FD

LDav

*78 (14/18)

*4 (2 -- 26)

*88 (36/41)

*6 (2 -- 94)

*44 (8/18)

*4 (2 -- 7)

*85 (35/41)

*9 (2 -- 100)

*64 (9/14)

*6 (3 -- 21)

*68 (15/22)

*6 (2 -- 57)


a -- Frequencies of expression decrease are shown as percentages. The number of cases with decreased expression and all tested samples are shown in parentheses.

b -- Level of expression decrease in tumor samples is shown in n-fold relative to expression in normal controls

* -- cases when decrease of target gene expression (FD and LDav) in tumor samples relative to normal controls was statistically valid according to the non-parametric Wilcoxon test (P ≤ 0.05 -0.001)

Bold font designates cases when: (i) FD and LDav for NPRL2 genes was more strongly pronounced in SCC than in AC samples according to the Mann -Whitney test (P = 0.002) and (ii) the difference of the FD and LDav for RASSF1A gene was statistically valid during AC progression according to the Mann -Whitney test (P < 0.05)

Underlined italics highlights positive tendency of FD and LDav differences of RBSP3, NPRL2 and RASSF1A genes during progression (AC and SCC respectively)

Senchenko et al. BMC Cancer 2010 10:75   doi:10.1186/1471-2407-10-75

Open Data